Express Healthcare
Home  »  News  »  Motilal Oswal Private Equity to invest Rs 2,400 million inMolbio Diagnostics

Motilal Oswal Private Equity to invest Rs 2,400 million inMolbio Diagnostics

0 64
Read Article

Molbio has developed, commercialised Truenat, commercial Point-of-Care molecular diagnostics platform using PCR technology

India Business Excellence Fund – III, a fund managed and advised by Motilal Oswal Private Equity (MOPE), have agreed to invest up to Rs 2,400 million inMolbio Diagnostics, a Goa based research driven diagnostic company.

Molbio (along with its subsidiary Bigtec labs) has developed and commercialised Truenat, a commercial Point-of-Care (PoC) molecular diagnostics platform using PCR (polymerase chain reaction) technology. Truenat can diagnose 22 infectious diseases (like TB, H1N1, dengue, HIV, hepatitis etc.) and has a pipeline of additional 43 diseases (such as coronavirus, MERS, etc.). This indigenous technology was approved by ICMR in 2018, after three years of validation study across various sites in India. Internationally, the World Health Organisation (WHO), after conducting a multi-country study, has released a rapid communication in January 2020 endorsing Truenat as initial diagnostic test of MTB and MTB-RIF in view of its high accuracy. The Truenat assay is rapid (results within 60 minutes) and affordable. The equipment is battery operated and can be used in peripheral centres without extensive infrastructure.

Molbio is working closely with central and state governments across India for supporting the national mission of TB eradication by 2025 and efficient diagnosis of H1N1, dengue, hepatitis B&C and other infectious diseases. As per the National Strategic Plan for TB Elimination of India, Government plans to establish over 8,000 molecular laboratories and diagnose over 1.5 crore patients’ annually using molecular tests by 2025. A phase wise roll out with 1,512 Truenat machines has already been initiated.

At present, Truenat devices are installed in over 500+ private labs and 350+ primary health centres in India and across the world in 27 countries. WHO endorsement will further enable the product to be commercialised across 150 + countries.

Vishal Tulsyan, Managing Director and CEO, MOPE commented, “We are very proud of partnering with an innovation led company that is likely to change diagnostic paradigm and have real impact on saving millions of life. Molbio has successfully innovated world’s first point of care molecular diagnostic platform and is a true testament to ‘Make in India’ for the world. Molbio’s business model of close ended diagnostic platform with multiple test assays have strong potential across the globe both in public and private sector. Through this partnership, we intend to help Molbio scale up their operations and achieve its vision of becoming a leading and well respected medical equipment company from India.”

Sriram Natarajan, Director and CEO, Molbio said, “Today, India has the highest TB burden across the globe and nearly 1,400 people die of TB every day. Truenat will help in decentralising and democratising access to high quality diagnostics to millions of patients suffering from TB and other infectious diseases even at peripheral and remote settings. Partnering with MOPE will accelerate Molbio’s growth plans and help the company in scaling its business. The funds would be utilised for fulfilling large committed orders, expansion of manufacturing facility and for other working capital and general corporate purposes.”

Chandrasekhar Nair, Co-Founder Bigtec, Director and CTO, Molbio said, “Truenat is patented across 100+ countries and has been a result of persistent effort of the dedicated Bigtec team with support from different Indian and global institutions. Truenat enables the transition from presumptive to efficient, real time and precise diagnosis of multiple diseases at reasonable price. Partnership with MOPE will enable us to increase the test menu, build scale and reach to primary healthcare centres and smaller diagnostics labs, which can now deliver high end molecular diagnostic test.”

Leave A Reply

Your email address will not be published.

Post Lockdown strategy: Addressing the new normal for staff, patients and attendants
Register Now
close-image